title: Buprenorphine for treating cancer pain.
abstract: BACKGROUND
  Many patients with cancer experience moderate to severe pain that requires treatment with strong analgesics. Buprenorphine, fentanyl and morphine are examples of strong opioids used for cancer pain relief. However, strong opioids are ineffective as pain treatment in all patients and are not well-tolerated by all patients. The aim of this Cochrane review is to assess whether buprenorphine is associated with superior, inferior or equal pain relief and tolerability compared to other analgesic options for patients with cancer pain.
  
  
  OBJECTIVE
  To assess the effectiveness and tolerability of buprenorphine for pain in adults and children with cancer.
  
  
  METHODS
  We searched CENTRAL (the Cochrane Library) issue 12 or 12 2014, MEDLINE (via OVID) 1948 to 20 January 2015, EMBASE (via OVID) 1980 to 20 January 2015, ISI Web of Science (SCI-EXPANDED & CPCI-S) to 20 January 2015, ISI BIOSIS 1969 to 20 January 2015. We also searched ClinicalTrials.gov (http://clinicaltrials.gov/; metaRegister of Controlled Trials (mRCT) (http://www.controlled-trials.com/mrct/), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (http://apps.who.int/trialsearch/) and the Proceedings of the Congress of the European Federation of International Association for the Study of Pain (IASP; via European Journal of Pain Supplements) on 16 February 2015. We checked the bibliographic references of identified studies as well as relevant studies and systematic reviews to find additional trials not identified by the electronic searches. We contacted authors of included studies for other relevant studies.
  
  
  METHODS
  We included randomised controlled trials, with parallel-group or crossover design, comparing buprenorphine (any formulation and any route of administration) with placebo or an active drug (including buprenorphine) for cancer background pain in adults and children.
  
  
  METHODS
  Two review authors independently extracted data pertaining to study design, participant details (including age, cancer characteristics, previous analgesic medication and setting), interventions (including details about titration) and outcomes, and independently assessed the quality of the included studies according to standard Cochrane methodology. As it was not feasible to meta-analyse the data, we summarised the results narratively. We assessed the overall quality of the evidence for each outcome using the GRADE approach.
  
  
  RESULTS
  In this Cochrane review we identified 19 relevant studies including a total of 1421 patients that examined 16 different intervention comparisons.Of the studies that compared buprenorphine to another drug, 11 studies performed comparative analyses between the randomised groups, and five studies found that buprenorphine was superior to the comparison treatment. Three studies found no differences between buprenorphine and the comparison drug, while another three studies found treatment with buprenorphine to be inferior to the alternative treatment in terms of the side effects profile or patients preference/acceptability.Of the studies that compared different doses or formulations/routes of administration of buprenorphine, pain intensity ratings did not differ significantly between intramuscular buprenorphine and buprenorphine suppository. However, the average severity of dizziness, nausea, vomiting and adverse events as a total were all significantly higher in the intramuscular group relatively to the suppository group (one study).Sublingual buprenorphine was associated with faster onset of pain relief compared to subdermal buprenorphine, with similar duration analgesia and no significant differences in adverse event rates reported between the treatments (one study).In terms of transdermal buprenorphine, two studies found it superior to placebo, whereas a third study found no difference between placebo and different doses of transdermal buprenorphine.The studies that examined different doses of transdermal buprenorphine did not report a clear dose-response relationship.The quality of this evidence base was limited by under-reporting of most bias assessment items (e.g., the patient selection items), by small sample sizes in several included studies, by attrition (with data missing from 8.2% of the enrolled/randomised patients for efficacy and from 14.6% for safety) and by limited or no reporting of the expected outcomes in a number of cases. The evidence for all the outcomes was very low quality.
  
  
  CONCLUSIONS
  Based on the available evidence, it is difficult to say where buprenorphine fits in the treatment of cancer pain with strong opioids. However, it might be considered to rank as a fourth-line option compared to the more standard therapies of morphine, oxycodone and fentanyl, and even there it would only be suitable for some patients. However, palliative care patients are often heterogeneous and complex, so having a number of analgesics available that can be given differently increases patient and prescriber choice. In particular, the sublingual and injectable routes seemed to have a more definable analgesic effect, whereas the transdermal route studies left more questions.
authors.affiliation: National Collaborating Centre for Cancer, 2nd Floor, Park House, Greyfriars Road, Cardiff, UK, CF10 3AF.
authors.forename: Mia
authors.initials: M
authors.lastname: Schmidt-Hansen
authors.forename: Nathan
authors.initials: N
authors.lastname: Bromham
authors.forename: Mark
authors.initials: M
authors.lastname: Taubert
authors.forename: Stephanie
authors.initials: S
authors.lastname: Arnold
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Hilgart
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000286:Administration, Sublingual; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D016032:Randomized Controlled Trials as Topic
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine
references.citation: J Pharmacol Exp Ther. 2000 Mar;292(3):1127-34
references.pmid: 10688632
references.citation: Int J Clin Pract Suppl. 2003 Feb;(133):15-8; discussion 23-4
references.pmid: 12665119
references.citation: Curr Pharm Des. 2004;10(7):717-32
references.pmid: 15032698
references.citation: J Pain Symptom Manage. 1992 May;7(4):209-13
references.pmid: 1517643
references.citation: Pain Pract. 2008 Jul-Aug;8(4):287-313
references.pmid: 18503626
references.citation: Clin Ther. 2007 Aug;29(8):1591-606
references.pmid: 17919542
references.citation: Ugeskr Laeger. 1982 May 3;144(18):1306-9
references.pmid: 6181598
references.citation: J Opioid Manag. 2007 Jul-Aug;3(4):195-206
references.pmid: 17957979
references.citation: Minerva Med. 1986 Jan 28;77(3-4):93-104
references.pmid: 3511410
references.citation: Br J Anaesth. 1990 Mar;64(3):276-82
references.pmid: 2328175
references.citation: Minerva Anestesiol. 1987 Apr;53(4):135-9
references.pmid: 2442668
references.citation: Anesteziol Reanimatol. 1994 Jul-Aug;(4):50-1
references.pmid: 7802320
references.citation: Clin Pharmacol Ther. 1989 Jan;45(1):66-71
references.pmid: 2491980
references.citation: Br J Clin Pharmacol. 1982 Apr;13(4):487-92
references.pmid: 7066163
references.citation: Pharmacotherapy. 1986 Sep-Oct;6(5):228-35
references.pmid: 3540873
references.citation: Br J Anaesth. 2006 May;96(5):627-32
references.pmid: 16547090
references.citation: J Pain Res. 2009 Sep 15;2:117-34
references.pmid: 21197300
references.citation: Paediatr Anaesth. 2011 Mar;21(3):280-90
references.pmid: 21091589
references.citation: Cochrane Database Syst Rev. 2013 Oct 05;(10):CD010270
references.pmid: 24096644
references.citation: Clin Ther. 2005 Feb;27(2):225-37
references.pmid: 15811486
references.citation: BMJ. 2008 Apr 26;336(7650):924-6
references.pmid: 18436948
references.citation: Clin J Pain. 1989 Jun;5(2):147-52
references.pmid: 2520396
references.citation: Clin Pharmacokinet. 1983 Jul-Aug;8(4):332-43
references.pmid: 6352139
references.citation: Cochrane Database Syst Rev. 2013 Jul 22;(7):CD003868
references.pmid: 23881654
references.citation: J Pain Symptom Manage. 2008 Aug;36(2):117-25
references.pmid: 18411010
references.citation: J Palliat Care. 1993 Autumn;9(3):44-6
references.pmid: 8271108
references.citation: Br J Anaesth. 2005 Jun;94(6):825-34
references.pmid: 15833777
references.citation: Pain. 1987 Jun;29(3):273-286
references.pmid: 3614964
references.citation: Clin Pharmacokinet. 2005;44(7):661-80
references.pmid: 15966752
references.citation: Ann Oncol. 2007 Sep;18(9):1437-49
references.pmid: 17355955
references.citation: Br J Clin Pharmacol. 1981 Aug;12(2):117-22
references.pmid: 7306425
references.citation: Pain Manag. 2012 Jul;2(4):351-62
references.pmid: 24654721
references.citation: Int J Clin Pract. 2008 Jan;62(1):152-6
references.pmid: 18173815
references.citation: Anaesthesia. 2013 Apr;68(4):400-12
references.pmid: 23347230
references.citation: Clin J Pain. 1999 Sep;15(3):166-72
references.pmid: 10524468
references.citation: Ther Clin Risk Manag. 2009 Oct;5(5):707-18
references.pmid: 19774212
references.citation: Clin Ther. 2004 Nov;26(11):1808-20
references.pmid: 15639693
references.citation: Gut. 1986 May;27(5):567-9
references.pmid: 3699566
references.citation: J Pain Palliat Care Pharmacother. 2011;25(1):6-18
references.pmid: 21426212
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Minerva Med. 1987 Aug 15;78(15):1177-81
references.pmid: 3302764
references.citation: Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003971
references.pmid: 17943808
references.citation: Pharmacol Rep. 2012;64(4):870-7
references.pmid: 23087138
references.citation: Gan To Kagaku Ryoho. 1982 Feb;9(2):250-7
references.pmid: 7184401
references.citation: Front Biosci. 2007 Jan 01;12:1291-9
references.pmid: 17127381
references.citation: Eur J Pain. 2009 Aug;13(7):737-43
references.pmid: 18977159
references.citation: Arzneimittelforschung. 1983;33(4):587-90
references.pmid: 6683540
references.citation: Anesthesiology. 2010 Jan;112(1):226-38
references.pmid: 20010421
references.citation: Drugs. 2003;63(19):1999-2010; discussion 2011-2
references.pmid: 12962515
references.citation: Cancer. 1987 Feb 15;59(4):850-6
references.pmid: 3802043
references.citation: Lancet. 2003 Apr 12;361(9365):1278
references.pmid: 12699963
references.citation: Eur J Pain. 2006 Nov;10(8):743-8
references.pmid: 16426877
references.citation: Clin Ther. 2006 Jun;28(6):943-52
references.pmid: 16860176
references.citation: J Palliat Med. 2008 Apr;11(3):492-501
references.pmid: 18363493
references.citation: Cancer. 1989 Jun 1;63(11 Suppl):2298-307
references.pmid: 2655867
references.citation: J Pain Symptom Manage. 2013 May;45(5):939-49
references.pmid: 23648060
references.citation: Clin Ther. 2003 Jan;25(1):150-68
references.pmid: 12637117
references.citation: Cochrane Database Syst Rev. 2015 Feb 27;(2):CD003870
references.pmid: 25723351
references.citation: Cochrane Database Syst Rev. 2002;(1):CD003447
references.pmid: 11869661
references.citation: Support Care Cancer. 2009 Jun;17(6):715-8
references.pmid: 19104845
references.citation: BMJ Support Palliat Care. 2016 Sep;6(3):292-306
references.pmid: 26669324
references.citation: Drugs. 1997;53 Suppl 2:40-9
references.pmid: 9190324
references.citation: Palliat Med. 2011 Jul;25(5):478-87
references.pmid: 21708854
references.citation: Minerva Anestesiol. 1985 Nov-Dec;51(11-12):609-14
references.pmid: 3836380
references.citation: Br J Clin Pharmacol. 1979;7 Suppl 3:315S-317S
references.pmid: 380617
references.citation: Brain Behav Immun. 2008 May;22(4):606-13
references.pmid: 18294814
references.citation: Int J Clin Pharmacol Res. 1996;16(4-5):109-16
references.pmid: 9172009
references.citation: Anesth Analg. 2000 Jun;90(6):1411-4
references.pmid: 10825330
references.citation: Anesth Analg (Paris). 1979;36(7-8):317-21
references.pmid: 525837
references.citation: Ugeskr Laeger. 1983 Oct 17;145(42):3236-40
references.pmid: 6197797
references.citation: Ann Oncol. 2008 Dec;19(12):1985-91
references.pmid: 18632721
references.citation: Pain Physician. 2011 May-Jun;14(3):219-48
references.pmid: 21587327